StoxRubicon Research vs Neuland Laboratories: share price & financials comparison
NSE: RUBICON vs NEULANDLAB · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Rubicon Research vs Neuland Laboratories at a glance
Rubicon Research (RUBICON) has a market capitalisation of ₹27,466 Cr, against ₹25,414 Cr for Neuland Laboratories (NEULANDLAB). Over the past year Rubicon Research has returned +176.3%, compared with +27.9% for Neuland Laboratories. On valuation, Neuland Laboratories trades at a lower P/E of 56.2 versus 84.6. Rubicon Research earns a higher return on equity (22.9% vs 22.3%). Rubicon Research comes out ahead on growth, momentum and technicals. Neuland Laboratories comes out ahead on size, valuation, profitability and financial health. Across the scored metrics below, Rubicon Research leads on 6 and Neuland Laboratories on 7. On StoxGud's 10-point checklist, Rubicon Research scores 8/10 and Neuland Laboratories scores 7/10.
| Metric | Rubicon Research | Neuland Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹27,466 Cr | ₹25,414 Cr |
| Revenue (latest FY) | ₹1,754 Cr | ₹2,023 Cr |
| Net profit (latest FY) | ₹247 Cr | ₹364 Cr |
| Valuation | ||
| P/E | 84.6 | 56.2 |
| P/B | 19.39 | 12.52 |
| Dividend yield | 0.00% | 0.06% |
| Profitability | ||
| Return on equity | 22.9% | 22.3% |
| Net profit margin | 15.5% | 19.6% |
| Operating margin | 23.8% | 30.6% |
| Growth | ||
| Revenue growth (YoY) | +39.9% | -12.6% |
| Net profit growth (YoY) | +68.0% | — |
| Revenue CAGR (multi-year) | — | +16.6% |
| Financial health | ||
| Debt to equity | 0.28 | 0.17 |
| Momentum | ||
| 1-month return | +5.3% | -9.0% |
| 1-year return | +176.3% | +27.9% |
| 3-year CAGR | — | +69.6% |
| 5-year CAGR | — | +64.0% |
| 10-year CAGR | — | +34.4% |
| Distance from 52W high | -10.8% | -17.9% |
| Technicals | ||
| RSI (14) | 65 | 50 |
| Price vs 200-day avg | +35.2% | +12.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Rubicon Research | Neuland Laboratories |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 8/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Rubicon Research or Neuland Laboratories?
Rubicon Research has a market cap of ₹27,466 Cr and Neuland Laboratories has a market cap of ₹25,414 Cr as of 06 Nov 2026.
Which has a lower P/E, Rubicon Research or Neuland Laboratories?
Neuland Laboratories has the lower P/E: Rubicon Research trades at 84.6 and Neuland Laboratories at 56.2.
Which gave better returns in the last year, Rubicon Research or Neuland Laboratories?
Rubicon Research did better: Rubicon Research returned +176.3% and Neuland Laboratories returned +27.9% over one year.
Is Rubicon Research or Neuland Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Rubicon Research scores 8/10 and Neuland Laboratories scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.